Clinical Trials on Relapsed and Refractory B-cell Non-Hodgkin Lymphoma in United Kingdom

Total 4210 results

Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | Relapsed Adult ALL | Relapsed CLL | Refractory B-Cell Small Lymphocytic Lymphoma

United States
Autolus Limited

Recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

United Kingdom
ADC Therapeutics S.A.

Recruiting

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

B-Cell Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-Cell Non-Hodgkin Lymphoma

United States, Spain, Italy, United Kingdom, Belgium, Czechia
Precision BioSciences, Inc.

Completed

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | B-cell Non Hodgkin Lymphoma | Leukemia, Lymphocytic, Chronic | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Chronic Lymphoid Leukemia in Relapse

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma

United States
Caribou Biosciences, Inc.

Recruiting

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Lymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's Lymphoma

United States, Australia, Israel
Affimed GmbH

Terminated

Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL

Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-Cell Non-Hodgkin Lymphoma

United States, Czechia, Germany, Poland
Dana-Farber Cancer Institute
HiberCell, Inc.

Completed

A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Non-Hodgkin's Lymphoma | Intermediate Grade B-Cell Non-Hodgkin's Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma

United States
PeproMene Bio, Inc.
City of Hope Medical Center

Recruiting

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

United States
Nationwide Children's Hospital

Not yet recruiting

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

Acute Lymphoblastic Leukemia, in Relapse | B Cell Leukemia | B-cell Non Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Acute Lymphoblastic Leukemia With Failed Remission

United States
National Cancer Institute (NCI)

Recruiting

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Small Lymphocytic Lymphoma | Recurrent Aggressive Non-Hodgkin Lymphoma | Refractory Aggressive Non-Hodgkin Lymphoma

United States
AstraZeneca
Parexel

Active, not recruiting

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

United States, Korea, Republic of, Canada, United Kingdom, Spain, France, Denmark
AIDS Malignancy Consortium
National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center

Not yet recruiting

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

HIV Infection | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Refractory Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma

United States
Kite, A Gilead Company

Active, not recruiting

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Spain, United States, Czechia, Sweden, Germany, Belgium, Italy, Canada, France, Netherlands, Poland
Adam Kittai

Recruiting

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed Non-Hodgkin Lymphoma | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Recurrent Transformed... and other conditions

United States
University of Nebraska
Bristol-Myers Squibb

Recruiting

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

Follicular Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma | Relapsed Non-Hodgkin Lymphoma | Mediastinal Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation Recipient

United States
Altor BioScience

Terminated

QUILT-3.002: ALT-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With... and other conditions

United States
Thomas Jefferson University
National Cancer Institute (NCI)

Recruiting

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Indolent Adult Non-Hodgkin...

United States
Nathan Denlinger
Bristol-Myers Squibb

Recruiting

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditions

United States
Caribou Biosciences, Inc.

Enrolling by invitation

Long-Term Follow-up Study (LTFS)

Lymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Hematologic Malignancy | Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Acute Myeloid Leukemia | Relapsed Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin's Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma

United States
Mustang Bio
National Cancer Institute (NCI)

Recruiting

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

Mantle Cell Lymphoma Recurrent | Mantle Cell Lymphoma Refractory | Small Lymphocytic Lymphoma, Relapsed | Waldenstrom's Macroglobulinemia Recurrent | Follicular B-cell Non-Hodgkin's Lymphoma | B-cell Lymphoma Refractory | Waldenstrom's Macroglobulinemia Refractory | Chronic Lymphoid Leukemia in Relapse

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
University of Washington
Janssen Pharmaceuticals

Active, not recruiting

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed B-Cell Non-Hodgkin Lymphoma

United States
Molecular Templates, Inc.

Terminated

PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma | Non-hodgkin Lymphoma,B Cell

United States
National Cancer Institute (NCI)

Completed

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed B-Cell Non-Hodgkin Lymphoma

United States
Fred Hutchinson Cancer Center
Mustang Bio

Recruiting

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic... and other conditions

United States
Mayo Clinic

Recruiting

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Indolent B-Cell Non-Hodgkin Lymphoma | Recurrent Indolent Non-Hodgkin Lymphoma | Refractory Indolent Non-Hodgkin Lymphoma | Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent B-Cell Non-Hodgkin Lymphoma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma

Non-Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory

United States
Janssen Research & Development, LLC
Mayo Clinic

Recruiting

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

United States, Australia, Israel
National Cancer Institute (NCI)

Completed

Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | CD20 Positive

United States
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Unknown

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

B-cell Non Hodgkin Lymphoma | Mature B-cell Leukemia Burkitt-type

Belgium, France, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain, China
Northwestern University
National Cancer Institute (NCI)

Recruiting

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent... and other conditions

United States
Fred Hutchinson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Terminated

huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Adult Acute Lymphoblastic Leukemia | Refractory Diffuse... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

Recurrent Mantle Cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin... and other conditions

United States
Fred Hutchinson Cancer Center
Faron Pharmaceuticals Ltd

Not yet recruiting

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Mantle Cell Lymphoma

United States
Janssen Research & Development, LLC
City of Hope Medical Center

Recruiting

A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

United States, Australia
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Recurrent Transformed Chronic Lymphocytic Leukemia | Refractory...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Recurrent Indolent Adult Non-Hodgkin Lymphoma

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Recurrent Indolent Adult Non-Hodgkin Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Recurrent... and other conditions

United States
University Hospital Southampton NHS Foundation...
Hoffmann-La Roche

Terminated

Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy (ARGO)

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United Kingdom
Sumithira Vasu
National Cancer Institute (NCI)

Recruiting

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent High Grade... and other conditions

United States

Clinical Trials on Relapsed and Refractory B-cell Non-Hodgkin Lymphoma in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations